Our research is focused on malignant brain tumours and aims to improve therapeutic options for these uncurable cancers. Patient tumors and patient derived xenograft models (PDX), which enable to translate novel treatment approaches into personalised medicine, are central to our work.

Our specific expertise and interests lie in tumour angiogenesis and invasion, tumour metabolism, and tumour cell heterogeneity and adaptability. Our research group is closely linked to the K.G. Jebsen Brain Tumour Research Center (University of Bergen, Norway), with joint research projects on glioma angiogenesis, metabolism and in vivo imaging, and has an extensive network of national and international collaborators.

Research projects

  • ADAPT: Adaptive capacities of glioblastoma: is there a role for cancer stem cells?
  • METABO: Aberrant tumour metabolism in gliomas.
  • INVGBM: Targeting glioma cell invasion.
  • CREG: Chemoresistance related RNAs in glioblastoma.
  • ANIMIX: Establishment of a national in vivo imaging platform.

Featured Publications

A DNA repair and cell cycle gene expression signature in primary and recurrent glioblastoma: prognostic value and clinical implications.

  • NORLUX-DNA repair and chemoresistance
  • Bioinformatics and Modelling
  • NORLUX-Glioma Biology
January 23, 2019
2019 Jan. Cancer Res. [Epub ahead of print].
  • Gobin M
  • Nazarov PV
  • Warta R
  • Timmer M
  • Reifenberger G
  • Felsberg J
  • Vallar L
  • Chalmers AJ
  • Herold-Mende CC
  • Goldbrunner R
  • Niclou SP
  • Van Dyck E.

RNAi/CRISPR Screens: from a Pool to a Valid Hit.

  • NORLUX-Glioma Biology
  • Bioinformatics and Modelling
  • NORLUX-DNA repair and chemoresistance
January 01, 2019
2019 Jan. Trends Biotechnol.37(1):38-55. Epub 2018 Aug 31.
  • Schuster A
  • Erasimus H
  • Fritah S
  • Nazarov PV
  • van Dyck E
  • Niclou SP
  • Golebiewska A.
See all publications


Simone Niclou


84, rue Val Fleuri
L-1526 Luxembourg
Tel. : +352 26970-273